Blind Spots in Breast Oncology: The Crisis of Lobular Carcinoma

BOSTON, MA – November 03, 2026 — In the high-stakes world of medical diagnostics, a "clear" mammogram is the ultimate reassurance. But for nearly 50,000 women in the United States each year, that reassurance is a dangerous illusion. Despite being the second most common form of breast cancer, invasive lobular carcinoma (ILC) remains a biological ghost—evading standard imaging, resisting traditional clinical trial protocols, and operating in a research landscape that has largely ignored its unique pathology.

This systemic blind spot has catalyzed a new national movement. A coalition of healthcare providers, intimately and personally affected by the disease, has launched Clinicians with Lobular Breast Cancer Speaking Out for Change (Clinicians with Lobular-SOC). Formed in partnership with the Lobular Breast Cancer Alliance (LBCA), the initiative aims to force a reckoning in breast oncology. Their mission is to train medical professionals, boost early diagnosis, and demand increased research funding for a disease that has been dangerously misunderstood for decades.

When the Doctor Becomes the Patient

The biological architecture of ILC is fundamentally different from the more common invasive ductal carcinoma (IDC). Rather than forming a distinct, palpable lump, ILC cells grow in thin, single-file strands. This diffuse, web-like infiltration makes the cancer notoriously difficult to detect through standard 2D or 3D mammography, ultrasound, and physical examination. Studies indicate that the detection rate for ILC on standard mammography can be as low as 57 percent, compared to up to 90 percent for IDC.

This diagnostic stealth spares no one—not even the experts. Dr. Sasha Stanton, a breast medical oncologist and founding member of the new coalition, experienced this firsthand.

"I am a breast oncologist and even I did not realize that when my mammogram was clear the symptoms I was feeling, which I should have known better not to ignore, were telling a different story," said Dr. Stanton. Six months after her diagnostic imaging showed no signs of concern, a follow-up MRI revealed Stage III invasive lobular carcinoma. The tumor had grown to over six centimeters and spread to four lymph nodes.

Dr. Stanton is not an anomaly within the medical community. The group includes eleven clinicians who have either faced an ILC diagnosis or lost a spouse to the disease. Dr. Tracy Cushing, an emergency medicine physician, notes the shocking lack of progress in understanding the disease since her days as a medical student over two decades ago. Dr. Maryanne Bombaugh, an OB/GYN, suffered a delayed diagnosis following clear mammograms. Dr. Kimberly Oney, a breast psychologist, was initially misdiagnosed with stomach cancer before learning she had de novo metastatic ILC. Tamra McDevitt, a neurology care coordinator, and Dr. John Doski, a pediatric surgeon who lost his wife to the disease, also bring their urgent perspectives to the coalition.

"We are relying on a screening infrastructure built for a different disease," noted one independent academic breast radiologist familiar with the coalition's work. "When we use tools optimized for detecting solid masses to find a cancer that presents like a spiderweb, we are setting both the patient and the physician up for failure."

The RECIST Catch-22: Locked Out of Innovation

The diagnostic failure is only the first systemic hurdle. Once diagnosed, patients face a secondary, structural barrier: they are routinely locked out of the clinical trials that offer access to cutting-edge therapies and drive the development of new standard-of-care treatments.

The culprit is a regulatory framework known as RECIST (Response Evaluation Criteria in Solid Tumors). RECIST guidelines are the gold standard used in oncology clinical trials to objectively measure how well a tumor responds to an experimental drug. However, RECIST relies on the presence of "measurable disease"—typically defined as a solid lesion with a longest diameter of at least 10 to 20 millimeters.

Because lobular cells infiltrate tissue diffusely rather than forming discrete, measurable masses, a vast majority of these tumors fail to meet RECIST criteria. Consequently, these patients are systematically excluded from breast cancer clinical trials.

"It is a devastating conversation to have with a patient," shared an independent clinical trial investigator. "You have a patient who desperately needs novel therapeutics, but because their cancer grows in sheets rather than spheres, the trial protocol dictates they are ineligible. It is a Catch-22 that halts scientific progress."

This exclusion creates a vicious cycle. Without these specific patients in clinical trials, researchers cannot generate the data necessary to develop targeted treatment protocols. As a result, the disease is often treated with the same therapeutic playbook as ductal carcinoma, despite mounting evidence that the two diseases respond differently to standard chemotherapies and endocrine treatments.

An Overlooked Epidemic and the Funding Gap

The scale of this oversight is staggering. ILC accounts for approximately 15 percent of all breast cancer diagnoses. With nearly 50,000 new cases annually in the U.S., it affects more women each year than ovarian cancer. Yet, it remains dramatically understudied and relatively unknown, both among the general public and primary care physicians.

Furthermore, the disease exhibits a distinct and troubling metastatic pattern. While ductal carcinomas typically spread to the liver, lungs, or brain, lobular carcinoma is known to metastasize to atypical locations, including the gastrointestinal tract, the peritoneum, the ovaries, and even the eye socket. Because the disease is so difficult to image, detecting a recurrence and monitoring metastatic progression is nearly impossible with standard scans.

Despite these alarming characteristics, federal research funding remains disproportionately low. While billions of dollars are allocated to general breast cancer research through agencies like the National Institutes of Health and the Department of Defense, the lion's share of that funding is directed toward ductal carcinoma, which is easier to study in laboratory cell lines and mouse models.

The Lobular Breast Cancer Alliance, founded by patients in 2017, has been fighting to close this gap. By partnering with affected clinicians, the advocacy effort is gaining a powerful new voice: the medical establishment itself.

Forcing a Systemic Shift in Oncology

The launch of this clinician-led initiative represents a critical inflection point. The group is leveraging their dual identities as medical insiders and cancer patients to demand structural changes across the continuum of care.

In the short term, the coalition is pushing for expanded clinician education. They aim to train primary care doctors and OB/GYNs to recognize the subtle, non-lump symptoms of the disease and to understand the severe limitations of standard mammography. There is also a growing push to clarify guidelines for advanced imaging modalities, such as MRI and Molecular Breast Imaging (MBI). While these tools offer significantly higher sensitivity, high costs, limited accessibility, and the risk of false positives currently prevent their use as standard supplemental screening for average-risk women.

Long-term solutions will require a paradigm shift in how breast cancer is classified, monitored, and treated. Oncology researchers are increasingly pointing to liquid biopsies and circulating tumor DNA (ctDNA) analysis as potential alternatives to traditional imaging. If researchers can track disease progression through blood markers rather than physical tumor measurements, it could bypass the RECIST hurdle and open the doors to adaptive clinical trial designs.

By stepping out of their roles as impartial providers and speaking as patients, these clinicians are stripping away the complacency surrounding breast cancer screening. Their message is unequivocal: the medical community can no longer afford to treat the second most common form of breast cancer as an afterthought. The technology and the protocols must evolve to meet the biology of the disease, ensuring that a clear scan finally means a clean bill of health.